Restem

RESTEM is a leading clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative cell therapies. The company focuses on pat

[Restem @restem_us]

DUX4 plays an important role in the biology of FSHD. When inappropriately active in muscle cells, it can contribute to muscle damage and progressive weakness.

Explore RESTEM’s work:
https://t.co/BQ0IXZ4qJe

#FSHD

[Restem @restem_us]

What does improvement mean in IIM? Measuring progress goes beyond a single symptom. Restem-L demonstrated meaningful, durable improvements in Total Improvement Score (TIS) in our Phase 1 trial.

Explore our work in IIM: https://t.co/J1KuZZPUMA

#Myositis

[Restem @restem_us]

FSHD can cause asymmetric muscle weakness, with one side of the body affected more than the other. Understanding these differences can help advance research and new approaches.

https://t.co/BQ0IXZ3STG

#FSHD

[Restem @restem_us]

Myth or fact? Understanding Idiopathic Inflammatory Myopathies (IIM) starts with separating misconceptions from reality.

Learn more about Restem-L:
https://t.co/J1KuZZPUMA

#Myositis

[Restem @restem_us]

Living with FSHD can affect much more than muscle strength. Everyday activities such as lifting, reaching, or climbing stairs may become increasingly challenging over time.

Learn more about RESTEM's development programs: https://t.co/BQ0IXZ3STG

#FSHD

[Restem @restem_us]

Progress in understanding complex muscle disorders continues to shape the future of care. In IIM, the immune system mistakenly attacks healthy muscle tissue, driving inflammation and muscle weakness. Learn more about Restem's research in IIM: https://t.co/J1KuZZPmX2
#Myositis

[Restem @restem_us]

Early recognition of FSHD can help improve disease awareness, support research, and expand opportunities to develop new treatment approaches.

Learn more about Restem's Phase 1/2 clinical trial:
https://t.co/BQ0IXZ4qJe

#FSHD

[Restem @restem_us]

FSHD is a progressive muscular dystrophy that can impact mobility and quality of life. RESTEM is advancing next-generation cell therapies for patients with unmet medical needs.

https://t.co/BQ0IXZ3STG

#FSHD #Celltherapy

[Restem @restem_us]

If you missed RESTEM CEO Andres Isaias' presentation at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference, you can now watch the webcast on our Corporate Presentations page.

Watch now: https://t.co/eJHkISYxMK

#Celltherapy

[Restem @restem_us]

A great moment from yesterday's BIO International Convention, where RESTEM CEO Andres Isaias presented on the future of cell and gene therapy and next-generation treatment approaches.

#BIO2026 #Celltherapy #GeneTherapy

[Restem @restem_us]

Join RESTEM CEO Andres Isaias at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. A live webcast will be available through the Investors section of our website.

Read the full release: https://t.co/VscJvtnP4f

#Celltherapy #Biotechnology

[Restem @restem_us]

Not all forms of IIM are the same. Conditions such as dermatomyositis, polymyositis, IMNM, and antisynthetase syndrome each present unique challenges. Understanding these differences is key to improving care and outcomes.
https://t.co/xHZ9msCfu9
#Myositis

[Restem @restem_us]

We are excited to present at the BIO International Convention 2026 in San Diego, where leaders from across the biotechnology industry come together to collaborate, innovate, and build new partnerships.

Read the full release: https://t.co/VscJvtnP4f

#BIO2026

[Restem @restem_us]

For patients living with IIM, new treatment approaches remain an important area of research. Restem-L is being developed as a cell therapy designed to modulate the immune system and address underlying disease activity in IIM.
https://t.co/J1KuZZPUMA
#Celltherapy #Biotech

[Restem @restem_us]

Great discussions at the 2026 Regenerative Medicine Symposium hosted by @UFMedicine. We enjoyed connecting with experts exploring advances in cell and gene therapies and the future of regenerative medicine. #RegenerativeMedicine #CellTherapy

[Restem @restem_us]

Living with IIM often means managing both the disease and the long-term effects of treatment. Phase 1 data showed Restem-L demonstrated clinically meaningful improvements in Total Improvement Score, along with evidence of reduced steroid use.
https://t.co/uot8pL3Uxj
#Celltherapy

[Restem @restem_us]

Muscle weakness is one of the most defining and impactful features of Idiopathic Inflammatory Myopathies (IIM). Restem-L demonstrated clinically meaningful improvements in muscle function and total improvement score (TIS).

https://t.co/xHZ9msCfu9

#Celltherapy #Clinicalresearch

[Restem @restem_us]

What is IIM? Idiopathic Inflammatory Myopathies are rare autoimmune diseases that can cause chronic inflammation and progressive muscle weakness. Restem-L is being developed as a new approach, advancing ongoing research in the disease.

https://t.co/J1KuZZPmX2

#Celltherapy

[Restem @restem_us]

May is Myositis Awareness Month, a time to recognize the patients, families, and healthcare professionals impacted by myositis. Raising awareness may help support earlier recognition, diagnosis, and research progress.

https://t.co/OF4kIi2veg

#MyositisAwarenessMonth

[Restem @restem_us]

#RESTEM announces first-patient-dosed in the Phase 1/2a study of Restem-L in facioscapulohumeral muscular dystrophy (FSHD). Learn more here https://t.co/qNkG1GdtIN

#FSHD #celltherapy #UMPCs #stemcells #nkcells #DMD #autoimmunediseases #secretome #exosomes